Clinical Trial

HIV Prevention With PrEP Among People on Opioid Replacement Therapy

Study acronym: OAT-PrEP
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-29.
Status change: Not Yet Recruiting → Recruiting 2025-10-01
Trial Details
NCT Number NCT07160075
Lead Sponsor Cara Spence
Collaborators: Gilead Sciences
Conditions HIV - Human Immunodeficiency Virus
Enrollment 350 participants
Start Date 2025-08-28
Primary Completion 2026-09-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-07